Modelling of the concentration—effect relationship of THC on central nervous system parameters and heart rate — insight into its mechanisms of action and a tool for clinical research and development of cannabinoids

Pharmacokinetics after pulmonary administration of δ-9-tetrahydrocannabinol (THC) and its major metabolites 11-OH-THC and 11-nor-9-COOH-THC was quantified. Additionally, the relationship between THC and its effects on heart rate, body sway and several visual analogue scales was investigated using pharmacokinetic—pharmacodynamic (PK-PD) modelling. This provided insights useful for the research and development of novel cannabinoids and the physiology and pharmacology of cannabinoid systems. First, the PK-PD model gave information reflecting various aspects of cannabinoid systems. The delay between THC concentration and effect was quantified in equilibration half-lives of 7.68 min for heart rate and from 39.2 to 84.8 min for the CNS responses. This suggests that the effect of THC on the different responses could be due to different sites of action or different physiological mechanisms. Differences in the shape of the concentration—effect relationship could indicate various underlying mechanisms. Second, the PK-PD model can be used for prediction of THC concentration and effect profiles. It is illustrated how this can be used to optimise studies with entirely different trial designs. Third, many new cannabinoid agonists and antagonists are in development. PK-PD models for THC can be used as a reference for new agonists or as tools to quantitate the pharmacological properties of cannabinoid antagonists.

[1]  A. Howlett,et al.  CB1 receptor–G protein association , 2001 .

[2]  M. Wall,et al.  The metabolism of delta 9-tetrahydrocannabinol and related cannabinoids in man. , 1981, Journal of clinical pharmacology.

[3]  D. Kendall,et al.  Cardiovascular effects of cannabinoids. , 2002, Pharmacology & therapeutics.

[4]  P. Netter Dopamine challenge tests as an indicator of psychological traits , 2006, Human psychopharmacology.

[5]  M. Wall,et al.  The Metabolism of Δ9‐Tetrahydrocannabinol and Related Cannabinoids in Man , 1981 .

[6]  M. Wall,et al.  Intravenous Injection in Man of Δ9-Tetrahydrocannabinol and 11-OH-Δ9-Tetrahydrocannabinol , 1972, Science.

[7]  C. Breivogel,et al.  Activation of cannabinoid receptors in rat brain by WIN 55212-2 produces coupling to multiple G protein alpha-subunits with different potencies. , 2000, Molecular pharmacology.

[8]  A. Cohen,et al.  Pharmacokinetic/pharmacodynamic Assessment of Tolerance to Central Nervous System Effects of a 3 mg Sustained Release Tablet of Rilmenidine in Hypertensive Patients , 2004, Journal of psychopharmacology.

[9]  M. Danhof,et al.  Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo. , 2005, Pharmacology & therapeutics.

[10]  L B Sheiner,et al.  Pharmacokinetic and pharmacodynamic modeling in vivo. , 1981, Critical reviews in bioengineering.

[11]  J. Gerven,et al.  The Application of the Principles of Clinical Drug Development to Pharmacological Challenge Tests of the Serotonergic System , 2004, Journal of psychopharmacology.

[12]  S. Heishman,et al.  Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. , 2001, Archives of general psychiatry.

[13]  G. Barnett,et al.  Marijuana effect and delta‐9‐tetrahydrocannabinol plasma level , 1984, Clinical pharmacology and therapeutics.

[14]  U. Ebert,et al.  Scopolamine model of dementia: electroencephalogram findings and cognitive performance , 1998, European journal of clinical investigation.

[15]  A. Howlett,et al.  CB1 receptor-G protein association. Subtype selectivity is determined by distinct intracellular domains. , 2001, European journal of biochemistry.

[16]  L B Sheiner,et al.  Estimating population kinetics. , 1982, Critical reviews in biomedical engineering.

[17]  A. V. D. Does,et al.  The effects of tryptophan depletion on mood and psychiatric symptoms. , 2001 .

[18]  R. Pertwee Pharmacology of cannabinoid CB1 and CB2 receptors. , 1997, Pharmacology & therapeutics.

[19]  A F Cohen,et al.  Estimating impossible curves using NONMEM. , 2003, British journal of clinical pharmacology.

[20]  G. Ertl,et al.  Cannabinoids Acting on CB1 Receptors Decrease Contractile Performance in Human Atrial Muscle , 2003, Journal of cardiovascular pharmacology.

[21]  A. Bond,et al.  The use of analogue scales in rating subjective feelings , 1974 .

[22]  M Danhof,et al.  Relevance of the Application of Pharmacokinetic-Pharmacodynamic Modelling Concepts in Drug Development , 1997, Clinical pharmacokinetics.

[23]  L B Sheiner,et al.  Simultaneous Modeling of Pharmacokinetics and Pharmacodynamics with a Nonparametric Pharmacodynamic Model , 1984, Clinical pharmacology and therapeutics.

[24]  S. Rietbrock,et al.  Concentration-effect relationship of delta-9-tetrahydrocannabiol and prediction of psychotropic effects after smoking marijuana. , 1997, International journal of clinical pharmacology and therapeutics.

[25]  France Mentré,et al.  Modelling and Simulation in the Development and use of Anti-Cancer Agents: An Underused Tool? , 2004, Journal of Pharmacokinetics and Pharmacodynamics.

[26]  R. Gieschke,et al.  Modelling Response Time Profiles in the Absence of Drug Concentrations: Definition and Performance Evaluation of the K–PD Model , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[27]  L Aarons,et al.  Role of modelling and simulation in Phase I drug development. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[28]  R. Rapaka,et al.  Pharmacokinetics and disposition of cannabinoids. , 1987, NIDA research monograph.

[29]  S. M. Owens,et al.  Kinetic study of smoking marijuana , 1982, Journal of Pharmacokinetics and Biopharmaceutics.

[30]  S. Goldberg,et al.  Cannabinoid CB1 Receptor Antagonists as Promising New Medications for Drug Dependence , 2005, Journal of Pharmacology and Experimental Therapeutics.

[31]  A F Cohen,et al.  Effect of intrapulmonary tetrahydrocannabinol administration in humans , 2008, Journal of psychopharmacology.

[32]  J. Hartigh,et al.  Effects of intravenous temazepam. II. A study of the long‐term reproducibility of pharmacokinetics, pharmacodynamics, and concentration‐effect parameters , 1994, Clinical pharmacology and therapeutics.

[33]  B. M. Wright A simple mechanical ataxia-meter. , 1971, The Journal of physiology.

[34]  Franjo Grotenhermen,et al.  Pharmacokinetics and Pharmacodynamics of Cannabinoids , 2003, Clinical pharmacokinetics.

[35]  B. Sadler,et al.  Metabolism, disposition, and kinetics of delta‐9‐tetrahydrocannabinol in men and women , 1983, Clinical pharmacology and therapeutics.

[36]  Wright Bm A simple mechanical ataxia-meter. , 1971 .

[37]  L. Hollister,et al.  Plasma delta‐9‐tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking , 1980, Clinical pharmacology and therapeutics.

[38]  A. Ameri The effects of cannabinoids on the brain , 1999, Progress in Neurobiology.

[39]  R. Hampson,et al.  Cannabinoid physiology and pharmacology: 30 years of progress , 2004, Neuropharmacology.

[40]  M. Widman Biliary excretion of ?1-tetrahydrocannabinol and its metabolites in the rat , 1974 .